The Utility of ctDNA to Detect and Monitor Minimal Residual Disease in Resected Stage IIB-IV Melanoma , Canada

Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties
Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group
Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Registration Status: Completed

Objective: On this study patients will have serial blood collections to measure ctDNA levels and assess its utility in early-stage melanoma. Study will investigate whether levels change immediately after surgery and while on drug treatment following surgery and whether ctDNA levels correlate with cancer recurrence.

Registered Biobank Name	The Utility of ctDNA to Detect and Monitor Minimal Residual Disease in Resected Stage IIB-IV Melanoma
Biobank Leader	Lejla Gavranovic
Country	Canada
Email for biobank inquiries	lgavran@bccancer.bc.ca
Principal Investigator	Dr. Alison Weppler
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Biospecimen Collected: